Article Sidebar

pdf
Date Published: 23/05/2025
Abstract Views: 50
Views pdf: 23
DOI: https://doi.org/10.51298/vmj.v550i2.14279
Issue
Vol. 550 No. 2 (2025)
Section
Các bài báo
How to Cite
Nguyễn Ngọc, C., Nguyễn Ngọc Uyên, C., & Nguyễn Minh, H. (2025). EVALUATION OF INTRAVITREAL BEVACIZUMAB THERAPY IN THE MANAGEMENT OF RETINOPATHY OF PREMATURITY IN EXTREMELY PREMATURE INFANTS AT THE NATIONAL CHILDREN’S HOSPITAL. Vietnam Medical Journal, 550(2). https://doi.org/10.51298/vmj.v550i2.14279

EVALUATION OF INTRAVITREAL BEVACIZUMAB THERAPY IN THE MANAGEMENT OF RETINOPATHY OF PREMATURITY IN EXTREMELY PREMATURE INFANTS AT THE NATIONAL CHILDREN’S HOSPITAL

Chung Nguyễn Ngọc, Chi Nguyễn Ngọc Uyên, Hằng Nguyễn Minh

Main Article Content

Abstract

Objective: Evaluation of intravitreal Bevacizumab therapy for retinopathy of prematurity in extremely premature infants with≤ 28 weeks' gestational age and/or 1000gram gestational ageat the National Children’s Hospital. Materials and methods: the study was conducted on patients diagnosed with retinopathy of prematurity ≤ 28 weeks' gestational age and/or 1000gram gestational age type 1 who underwent intravitreal Bevacizumab injection at the National Children’s Hospital. This retrospective cross-sectional descriptive study encompasses Results: 96 eyes of 48 patients. 87(90,6%) eyes had complete regression, 7(7,3%) eyes not had complete regression, 2(2,08) eyes retinal detachment. Conclusion: treatment intravitreal Bevacizumab injection for ROP and results 90,6% eyes had complete regression.

Article Details

References

1. Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024-1028.
2. Hakeem A, Mohamed G, Othman M. Retinopathy of prematurity: a study of prevalence and risk factors. Middle East Afr J Ophthalmol. 2012;19(3): 289-294.
3. Section on ophthalmology American academy of pediatrics, American academy of ophthalmology, American association for pediatric ophthalmology and strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2006;117(2): 572-576.
4. Good W. Early treatment for retinopathy of prematurity cooperative group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102: 2 33-248; discussion 248-250.
5. Gilbert C, Fielder A, Gordillo L, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics. 2005;115(5):e518-525.
6. Hwang C, Hubbard G, Hutchinson A, et al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: Afive yearsretrospective analysis. Ophthalmology. 2015;122(5):1008-1015.
7. Nguyễn Xuân Tịnh (2012), Điều trị bệnh võng mạc trẻ đẻ non hình thái nặng bằng tiêm thuốc Bevacizumab (Avastin) nội nhãn - kết quả sau hơn một năm theo dõi. Tạp chí Nhãn khoa Việt Nam. 2012 (28).
8. Phan Đình Toàn (2012), Đặc điểm lâm sàng bệnh võng mạc trẻ đẻ non hình thái nặng và kết quả ban đầu điều trị bằng Avastin nội nhãn. Luận văn thạc sỹ Nhãn khoa, Trường Đại học Y Hà Nội.
9. Isaac M, Mireskandari K, Fallaha N, et al. Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience. Can J Ophthalmol. 2023;58(6):553-558.
10. Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42(3):462-469.